Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

How vaccine platforms are shaping preparedness for emerging and re-emerging viruses alike.

Created on 13 Nov 2026

Authors

Daniel M Jones, Sarah C Gilbert

Published in

Current opinion in virology. Volume 77. Pages 101595. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Vaccine platforms are validated, adaptable technologies designed to enable a 'plug-and-play' approach to vaccine development and deployment, and have emerged as a cornerstone for epidemic and pandemic preparedness due to their capacity to be rapidly tailored to emerging pathogens. This capability was demonstrated during the COVID-19 pandemic, when the first clinical trial of a SARS-CoV-2 vaccine was initiated just 66 days after the viral genome was published. However, outbreaks caused by novel emerging viruses like SARS-CoV-2 are less common than those caused by known, re-emerging pathogens, including Marburg, Nipah and Lassa viruses. Unlike SARS-CoV-2, these pathogens have been recognised as public health threats for decades, yet licensed vaccines against them have yet to be realised. While this gap is partly attributable to scientific shortfalls, a more significant factor has arguably been the combination of economic, regulatory and epidemiological challenges that have impeded vaccine licensure and stockpile establishment. This review discusses how vaccine platforms are addressing some of these challenges, potentially providing the foundation for much-needed vaccine stockpiling approaches against re-emerging pathogens.

PMID:
43019871
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement